Aaron Sverdlov, Co-Director of the Newcastle Centre of Excellence in Cardio-Oncology at Hunter Medical Research Institute (HMRI), shared a post on LinkedIn about a paper he co-authored with colleagues published in the Journal of Thrombosis and Thrombolysis:
“New publication alert.
Happy to share our new review on tyrosine kinase inhibitors (TKIs) and the real-world balance between thrombosis and bleeding.
Why this matters (especially for interventional cardiologists):
- Arterial risk: more pronounced with VEGFR and BCR-ABL TKIs – plan PCI and secondary prevention accordingly.
- Bleeding risk: BTK inhibitors drive platelet-function issues – adapt DAPT/anticoagulation and peri-op plans.
- What to do: baseline CV/bleeding risk, proactive risk-factor control, and MDT cardio-oncology workflows.
Led by our CardioOncology Fellow Lloyd Butel-Simoes and co-authored by the cardiovascular team from Hunter New England Local Health District and the International Cardio-Oncology Society Newcastle Center of Excellence in Cardio-Oncology.”
Title: Tyrosine kinase inhibitors – balancing the haemostatic scales: a review of associated thrombosis and bleeding
Authors: Lloyd E. Butel-Simoes, Ammar Albayati, Jie Yu, Thomas Quirk, Shanathan Sritharan, Matthew French, Joshua D. Bennetts, Doan T. M. Ngo, Aaron L. Sverdlov
You can read the Full Article in the Journal of Thrombosis and Thrombolysis.
More posts featuring Aaron Sverdlov.